ADC Therapeutics SA

Listed Company

ADCTCIK 0001771910NYSENon-AcceleratedSmaller ReportingPharmaceutical PreparationsV8CHFY ends Dec 31

Period

FY 2025

Revenue

$81.36M

Net Income

$-142.62M

Total Assets

$323.15M

Equity

$-185.83M

Shares Out

127.19M

Op. Cash Flow

$-141.17M

ADCT$1.36−56.43% · past yearDBEQ Basic

Daily closing prices

Business

ADC Therapeutics is a commercial-stage global biopharmaceutical company pioneering antibody-drug conjugates (ADCs) for oncology. The company's approved product is ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC for relapsed or refractory diffuse large B-cell lymphoma, with regulatory approvals in the United States, Europe, China, and Canada. The company is expanding ZYNLONTA into earlier treatment lines and additional lymphoma indications through clinical trials, while developing next-generation ADCs including ADCT-241 targeting prostate-specific membrane antigen for prostate cancer. ADC Therapeutics operates globally with headquarters in Switzerland and commercializes ZYNLONTA in the United States through its own sales force while utilizing strategic partnerships in international markets.

Summary from 10-K filed 2026-03-10

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Total revenue, net	81	71	70	210
Cost of product sales	−6	−6	−3	−3
Research and development	−104	−110	−127	−186
Selling and marketing	−43	−44	−57	−69
General and administrative	−37	−42	−48	−74
Restructuring, impairment and other related costs	−13	0	—	—
Total operating expense	−203	−201	−236	−333
Loss from operations	−121	−131	−166	−123
Interest income	9	12	11	3
Interest expense	−52	−50	−46	—
Other, net	23	12	6	53
Total other expense, net	−20	−25	−29	−23
Loss before income taxes	−142	−156	−195	−147
Income tax expense	−1	−200,000	−39	−227,000
Loss before equity in net losses of joint venture	−143	−156	−235	−147
Equity in net losses of joint venture	0	−2	6	10
Net loss	−143	−158	−240	−157
Net loss per share, basic (in dollars per share)	−1.12	−1.62	−2.94	−2.01
Net loss per share, diluted (in dollars per share)	−1.12	−1.62	−2.94	−2.01
Weighted average shares outstanding, basic (in shares)	127	97	82	78
Weighted average shares outstanding, diluted (in shares)	127	97	82	78

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	261	251	279	326	—
Accounts receivable, net	29	20	25	73	—
Inventory	4	2	16	12	—
Prepaid expenses	6	8	10	23	—
Other current assets	6	9	6	—	—
Total current assets	306	291	336	435	—
Inventory, long-term	14	16	—	—	—
Property and equipment, net	0	5	6	3	—
Operating lease right-of-use assets	1	8	11	7	—
Other long-term assets	1	1	711,000	902,000	—
Total assets	323	322	355	491	—
Accounts payable	9	18	16	12	—
Accrued expenses and other current liabilities	58	62	52	68	—
Senior secured term loans, current portion	3	0	—	—	—
Total current liabilities	70	80	68	82	—
Deferred royalty obligation, long-term	323	320	304	212	—
Senior secured term loans, long-term	112	114	113	110	—
Operating lease liabilities, long-term	1	8	10	7	—
Other long-term liabilities	3	2	9	838,000	—
Total liabilities	509	525	503	411	—
Commitments and contingencies (Note 14)	—	—	—	—	—
Common shares, at CHF 0.08 par value	11	8	7	7	—
Additional paid-in capital	1,440	1,284	1,181	1,166	—
Treasury shares	−205,000	−220,000	−541,000	−679,000	—
Accumulated other comprehensive loss	−517,000	−1	−93,000	2	—
Accumulated deficit	−1,636	−1,493	−1,335	−1,095	—
Total shareholders (deficit) equity	−186	−203	−148	79	154
Total liabilities and shareholders (deficit) equity	323	322	355	491	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Share-based compensation expense	7	7	13	49
Accretion expense of deferred royalty obligation	29	28	19	12
Cumulative catch-up adjustment, deferred royalty obligation	−22	−11	−5	−15
Write-downs of inventory	2	2	2	2
Depreciation	705,000	1	1	1
Amortization of operating lease right-of-use assets	1	2	2	1
Amortization of debt discount, senior secured term loan	2	902,000	—	—
Impairment of long-lived assets and prepaid expenses and other related costs	7	0	—	—
Other	304,000	−669,000	52,000	91,000
Accounts receivable, net	−9	5	48	−43
Inventory	−2	−4	−6	−10
Prepaid expenses and other current assets	5	−1	7	−11
Other long-term assets	−46,000	−456,000	200,000	−210,000
Accounts payable	−9	2	3	310,000
Accrued expenses and other current liabilities	−7	11	−14	16
Operating lease liabilities	−3	−2	−2	−1
Other long-term liabilities	−410,000	−7	7	0
Net cash used in operating activities	−141	−124	−119	−138
Payment for purchases of property and equipment	−264,000	−867,000	−3	−687,000
Proceeds from the sale of equipment	659,000	0	—	—
Net cash provided by (used in) investing activities	395,000	−867,000	−3	−687,000
Proceeds from sale of common shares, net of transaction costs	86	61	0	—
Proceeds from Pre-Funded Warrants, net of transaction costs	65	37	0	—
Proceeds from share issuance under stock purchase plan	271,000	558,000	773,000	0
Proceeds from the exercise of options	534,000	228,000	0	—
Taxes paid related to net settled equity awards	−2	−1	0	−1
Net cash provided by financing activities	151	97	74	−897,000
Net decrease in cash and cash equivalents	10	−28	−48	−140
Exchange (losses)/gains on cash and cash equivalents	305,000	−83,000	184,000	−208,000
Interest paid	14	16	15	10
Interest received	9	14	10	2
Payments made under royalty financing transaction	−6	−5	−9	−11
Transaction costs recorded in Accounts payable and other current liabilities and Other long-term liabilities	837,000	0	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is ADC Therapeutics SA's CIK number?

ADC Therapeutics SA's SEC CIK number is 0001771910 (1771910). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find ADC Therapeutics SA's SEC filings?

All of ADC Therapeutics SA's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did ADC Therapeutics SA last report earnings?

ADC Therapeutics SA (ADCT) most recently filed an earnings 8-K with the SEC on May 4, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-029524). This is ADC Therapeutics SA's most recent earnings filing of record — not a forecast of its next earnings date.

What is ADC Therapeutics SA's most recent earnings 8-K?

ADC Therapeutics SA's latest earnings 8-K (Item 2.02) was filed May 4, 2026 under accession 0001628280-26-029524. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View ADC Therapeutics SA's latest earnings 8-K →
Look up any company's CIK number →